NeoGenomics To Attend The 16th Annual Craig-Hallum Institutional Investor Conference

FT. MYERS, FL / ACCESWIRE / May 23, 2019 / NeoGenomics, Inc. (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chief Executive Officer, Sharon Virag, Chief Financial Officer, and Bill Bonello, Chief Strategy and Corporate Development Officer, Director of Investor Relations, will be conducting one-on-one meetings with investors at the 16th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 29, 2019 in Minneapolis, MN.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Companys Pharma Services division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit.

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including the information set forth in the Full-Year 2019 Financial Outlook. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Companys ability to continue gaining new customers, offer new types of tests, integrate its acquisition of the Genoptix business and otherwise implement its business plan, as well as additional factors discussed under the heading Risk Factors and elsewhere in the Companys Annual Report on Form 10-K filed with the SEC on February 26, 2019, amended by a 10K/A filed with the SEC on May 8, 2019. As a result, this press release should be read in conjunction with the Companys periodic filings with the SEC. In addition, it is the Companys practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at

Forward-looking statements represent the Companys estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Companys estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

Chief Strategy and Corporate Development Officer

[emailprotected]EDITORIALToll Free: 888.952.4446 Opt 1